Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Guilford's neuroimmunophilin ligand program

July 4, 1997

Selective 5-HT1D receptor agonist active in two migraine models

July 4, 1997

FDA approves Mirapex for the treatment of Parkinson's disease

July 3, 1997

CoCensys reports on phase II trial with ganaxolone

July 2, 1997

Full 5-HT1A receptor antagonist described by Duphar

July 2, 1997

Human PEP inhibitor isolated from microbial sources

July 2, 1997

Potent and selective dopamine D3 ligands from ADIR

July 2, 1997

Algene and Janssen extend collaboration in genetic study of schizophrenia

July 1, 1997

Neuroprotective effects of NMDA antagonists in animal models

July 1, 1997

MS-322: new centrally acting muscle relaxant with little CNS depressant activity

July 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...